Journal
INFLAMMATORY BOWEL DISEASES
Volume 22, Issue 7, Pages 1737-1743Publisher
OXFORD UNIV PRESS INC
DOI: 10.1097/MIB.0000000000000808
Keywords
Crohn's disease; ulcerative colitis; monoclonal antibody; immunogenicity
Categories
Funding
- Abbott
- ActoGeniX NV
- AGI Therapeutics Inc.
- Alba Therapeutics Corp.
- Albireo
- Alfa Wasserman
- Amgen
- AM-Pharma BV
- Anaphore
- Astellas
- Athersys Inc.
- Atlantic Healthcare Ltd.
- Aptalis
- BioBalance Corp.
- Boehringer-Ingelheim
- Bristol-Myers Squibb
- Celgene
- Celek Pharmaceuticals
- Cellerix SL
- Cerimon Pharmaceuticals
- ChemoCentryx
- CoMentis
- Cosmo Technologies
- Coronado Biosciences
- Cytokine Pharmasciences
- Eagle Pharmaceuticals
- EnGene Inc.
- Eli Lilly
- Enteromedics
- Exagen Diagnostics Inc.
- Ferring Pharmaceuticals
- Flexio Therapeutics Inc.
- Funxional Therapeutics Ltd.
- Genzyme Corp.
- Gilead Sciences
- Given Imaging
- GSK
- Human Genome Sciences
- Ironwood Pharmaceuticals
- KaloBios Pharmaceuticals
- Lexicon Pharmaceuticals
- Lycera Corp.
- Meda Pharmaceuticals
- Merck Research Laboratories
- Merck Serono
- Millenium Pharmaceuticals
- Nisshin Kyorin Pharmaceuticals
- Novo Nordisk
- NPS Pharmaceuticals
- Optimer Pharmaceuticals
- Orexigen Therapeutics Inc.
- PDL Biopharma
- Pfizer
- Procter and Gamble
- Prometheus Laboratories
- ProtAb Ltd.
- Purgenesis Technologies Inc.
- Relypsa Inc.
- Roche
- Salient Pharmaceuticals
- Salix Pharmaceuticals
- Santarus
- Schering Plough
- Shire Pharmaceuticals
- Sigmoid Pharma Ltd.
- Sirtris Pharmaceuticals
- SLA Pharma UK Ltd.
- Targacept
- Teva Pharmaceuticals
- Therakos
- Tillotts Pharma AG
- TxCell SA
- UCB Pharma
- Viamet Pharmaceuticals
- Vascular Biogenics Ltd.
- Warner Chilcott UK Ltd.
- Wyeth
- Genentech
- Janssen
- Milennium Pharmaceuticals
- Novartis
- Abbvie
- Merck
- Takeda
- Genentech/Roche
- Galapagos
- hospira Mundipharma
- Ferring
- Shire
- Tillotts Pharma
- Hospira
- Takeda Pharma
- Millennium Pharmaceuticals
- Novartis Pharmaceuticals
- Biotech/Centocor Inc.
- Elan/Biogen
- Roche/Genentech
- ActoGenix
- Wyeth Pharmaceuticals Inc.
- Astra Zeneca Janssen/JnJ (Canada, USA)
- Astra Zeneca Janssen/JnJ (Global)
- Sanofi
- Centocor Inc.
- Janssen-Ortho
- Abbott Labs
- Astra Zeneca
- Serono
- Unity Pharmaceuticals
- Albireo Pharma
- Given Imaging Inc.
- Novonordisk
- Prometheus Therapeutics and Diagnostics
- Athersys
- Axcan
- Gilead
- Zealand Pharma
- Zyngenia
- GiCare Pharma Inc.
- Sigmoid Pharma
Ask authors/readers for more resources
Multiple new biological treatments for Crohn's disease and ulcerative colitis are becoming available. Specifically, vedolizumab and ustekinumab are monoclonal antibodies that target molecular pathways relevant to disease pathogenesis. What can Cochrane reviews tell us about the efficacy, safety, and immunogenicity of these new agents? A Cochrane inflammatory bowel disease group symposium held at the 2015 Digestive Diseases Week annual meeting addressed these questions. This article reviews the data presented at that session.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
